Metastatic bone pain: treatment options with an emphasis on bisphosphonates

被引:55
作者
von Moos, Roger [1 ]
Strasser, Florian [2 ]
Gillessen, Silke
Zaugg, Kathrin [3 ]
机构
[1] Kantonsspital Graubunden, CH-7000 Chur, Switzerland
[2] Kantonsspital, Dept Internal Med, Palliat Med Sect Oncol, CH-9007 St Gallen, Switzerland
[3] Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland
关键词
metastatic bone disease; skeletal-related events; bone pain; bisphosphonates; analgesic;
D O I
10.1007/s00520-008-0487-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Introduction One of the key targets for metastatic cancer cells is the skeleton. Once metastatic cells are established within the bone matrix, skeletal integrity becomes increasingly compromised. Bone lesions lead to various complications, including bone pain, fractures and spinal cord compression. Mechanisms of bone pain Bone pain is debilitating and affects quality of life of the patient. In addition, it increases the use of health care resources. Many patients with metastatic bone disease experience substantial bone pain despite state-of-the-art systemic analgesic treatment. Incident pain is the predominant pain syndrome. Treatment options for bone pain Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses. Other techniques for treating bone pain, including radiation therapy, neuraxial application of analgesics, nerve blocks and local stabilisation procedures, should be considered. In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease.
引用
收藏
页码:1105 / 1115
页数:11
相关论文
共 104 条
[1]
Anselmetti GC, 2005, RADIOL MED, V110, P262
[2]
Banerjee D, 2003, AM J KIDNEY DIS, V41
[3]
A REVIEW OF LOCAL RADIOTHERAPY IN THE TREATMENT OF BONE METASTASES AND CORD COMPRESSION [J].
BATES, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01) :217-221
[4]
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[5]
Preclinical perspectives on bisphosphonate renal safety [J].
Body, JJ ;
Pfister, T ;
Bauss, F .
ONCOLOGIST, 2005, 10 :3-7
[6]
Bisphosphonates in the treatment of metastatic breast cancer [J].
Body, JJ .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) :477-485
[7]
Bisphosphonates for cancer patients: why, how, and when? [J].
Body, JJ ;
Mancini, I .
SUPPORTIVE CARE IN CANCER, 2002, 10 (05) :399-407
[8]
Bisphosphonates for metastatic bone pain [J].
Body, JJ .
SUPPORTIVE CARE IN CANCER, 1999, 7 (01) :1-3
[9]
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer [J].
Body, JJ ;
Diel, IJ ;
Bell, R ;
Pecherstorfer, M ;
Lichinitser, MR ;
Lazarev, AF ;
Tripathy, D ;
Bergström, B .
PAIN, 2004, 111 (03) :306-312
[10]
Chang JT, 2003, NEW ENGL J MED, V349, P1676